A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Idelalisib (Primary) ; Bendamustine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 12 Dec 2017 Results (n=853) of ad hoc analysis assessing rates of grade more than or equal to 3 transaminase elevation using patient data from this and other 5 trials presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 24 Jun 2016 Status changed from active, no longer recruiting to discontinued.
    • 22 Apr 2016 EudraCT reports trial status as prematurely ended in Hungary, Belgium and Croatia, Italy (end date:2016-03-08) and Poland (end date: 2016-03-11).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top